Wechselwirkungen · Usymro
Usymro 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-153101 · Präparat HOS-100925
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored. There were no indications of an interaction with these concomitantly administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6- mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T13:10:00Z · SHA-256 274a2e52e504e4f872783b2297b7ce22f2f8fa38a366b8eaea4a5c9ad8e0746b · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 552–1581 im Abschnitt